CSLCSLLY -2.30%73 EPS without NRI is $0.90 as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.49 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,176 Biotechnology companies, CSL ranks worse than 56.63% on this metric.
CSL's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was $0.90.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $0.90.
During the past 12 months, CSL's average earnings per share (NRI) Growth Rate was -33.70% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 11.50% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 6.80% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for CSL's EPS without NRI or its related term are showing as below:
CSLLY'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0.1 Med: 13.85 Max: 107.8
Current: 11.5
During the past 13 years, CSL's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 107.80% per year. The lowest was 0.10% per year. And the median was 13.85% per year.
CSLLY's 3-Year EPS without NRI Growth Rate is ranked worse than 56.63% of 1176
companies
in the Biotechnology industry
Industry Median: 16.8
vs CSLLY: 11.50
CSL's EPS (Diluted) for the
six
months ended in Dec. 2025 was $0.21.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.21.
CSL's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.21.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.21.
CSL (OTCPK:CSLLY) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
CSL EPS without NRI Related Terms
CSL EPS without NRI Historical Data
* Premium members only.
The historical data trend for CSL's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, CSL's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where CSL's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a EPS without NRI of $0.90 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #666 out of 1176 companies in the Biotechnology industry, placing it in the top 56.6%.
Is CSL's EPS without NRI too high?
CSL's current EPS without NRI is $0.90. The Biotechnology industry median EPS without NRI is 16.80. CSL's value of $0.90 is 94.6% below this industry median. Based on the distribution chart, CSL ranks #666 out of 1176 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #666 out of 1176 companies for EPS without NRI. This places CSL in the lower half of its industry. The industry median EPS without NRI is 16.80. CSL's value of $0.90 is 94.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current EPS without NRI of $0.90 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on CSL and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current EPS without NRI is $0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current EPS without NRI is $0.90 and 94.6% below the Biotechnology industry median of 16.80. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For CSL (CSLLY), the current EPS without NRI is $0.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
EPS without NRI: $0.90
GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
Industry Position: 94.6% below the Biotechnology median (#666 of 1176)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
